Skip to main content
Venetoclax achieves a high undetectable measurable residual disease rate in ibrutinib-treated high-risk CLL
Primary tabs
•••
View
Get Stamp Tags
Published Locations
Breadcrumb
Home
Venetoclax achieves a high undetectable measurable residual disease rate in ibrutinib-treated high-risk CLL
User login
Username
Password
Reset your password
Concept
Lead
score
Chronic Lymphocytic Leukemia
1
1
Chemotherapy
0
1
Residual Disease
0
0.88
Leukemia
0
0.35
Bone Marrow
0
0.25
Specialty
Lead
score
Hematology-Oncology
1
1
Edit Tags